Well being Canada Releases Up to date Warnings About Elmiron Associated Imaginative and prescient Loss
To print this text, all you want is to be registered or login on Mondaq.com.
Well being Canada launched a Dear Health Professional
Letter on December 15, 2020 to advise healthcare professionals,
together with urologists, urogynecologists, ophthalmologists,
optometrists, household physicians, and pharmacists about circumstances of
pigmentary maculopathy reported with use of Elmiron.
As mentioned in our previous post Elmiron is a medicine
prescribed to deal with interstitial cystitis and has been linked to
imaginative and prescient loss.
Instances of pigmentary maculopathy, which entails adjustments to the
retina that may trigger imaginative and prescient loss and impairment, have been
reported with Elmiron utilization. People who’ve used Elmiron for
three years or longer are notably in danger.
The Well being Canada publication advises healthcare professionals
of the chance of pigmentary maculopathy with Elmiron and
contraindicates the drug in sufferers with a historical past of macular
The Canadian Product Monograph for Elmiron has been up to date to
embrace the contraindication and to supply details about the
danger of pigmentary maculopathy.
Siskinds LLP has commenced class proceedings on behalf of
Canadians which have suffered imaginative and prescient impairment associated to the utilization
of Elmiron. Siskinds LLP is offered and prepared to evaluation and
focus on your potential case. If you happen to or a beloved one has suffered
imaginative and prescient impairment or damage following utilization of Elmiron, please
contact our medical product legal responsibility staff for the category motion
Initially Revealed by Siskinds, December 2020
The content material of this text is meant to supply a basic
information to the subject material. Specialist recommendation must be sought
about your particular circumstances.
POPULAR ARTICLES ON: Meals, Medication, Healthcare, Life Sciences from Canada